Concepts (302)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Low Back Pain | 12 | 2020 | 45 | 2.970 |
Why?
|
| Analgesics, Opioid | 14 | 2022 | 231 | 1.920 |
Why?
|
| Pain, Postoperative | 10 | 2019 | 178 | 1.810 |
Why?
|
| Autonomic Nerve Block | 3 | 2015 | 10 | 1.470 |
Why?
|
| Pain Measurement | 18 | 2020 | 351 | 1.240 |
Why?
|
| Analgesics | 9 | 2018 | 109 | 1.120 |
Why?
|
| Perioperative Care | 3 | 2019 | 59 | 1.060 |
Why?
|
| Sacroiliac Joint | 3 | 2014 | 12 | 0.980 |
Why?
|
| Midazolam | 2 | 2014 | 10 | 0.960 |
Why?
|
| Diagnostic Techniques and Procedures | 2 | 2014 | 7 | 0.960 |
Why?
|
| Conscious Sedation | 2 | 2014 | 24 | 0.960 |
Why?
|
| Anesthetics, Intravenous | 2 | 2014 | 17 | 0.950 |
Why?
|
| Fentanyl | 2 | 2014 | 33 | 0.950 |
Why?
|
| Complex Regional Pain Syndromes | 2 | 2014 | 19 | 0.940 |
Why?
|
| Patient Satisfaction | 2 | 2016 | 240 | 0.900 |
Why?
|
| Primary Health Care | 6 | 2022 | 225 | 0.890 |
Why?
|
| Pain | 7 | 2012 | 287 | 0.880 |
Why?
|
| Obesity | 5 | 2014 | 1158 | 0.870 |
Why?
|
| gamma-Aminobutyric Acid | 4 | 2008 | 75 | 0.840 |
Why?
|
| Osteoarthritis, Knee | 1 | 2023 | 90 | 0.830 |
Why?
|
| Humans | 58 | 2023 | 31836 | 0.820 |
Why?
|
| Opioid-Related Disorders | 6 | 2019 | 54 | 0.750 |
Why?
|
| Electronic Health Records | 3 | 2019 | 159 | 0.730 |
Why?
|
| Fear | 3 | 2014 | 48 | 0.670 |
Why?
|
| Buprenorphine | 1 | 2019 | 13 | 0.660 |
Why?
|
| Treatment Outcome | 15 | 2023 | 3294 | 0.640 |
Why?
|
| Zygapophyseal Joint | 2 | 2007 | 3 | 0.600 |
Why?
|
| Resistance Training | 2 | 2014 | 79 | 0.570 |
Why?
|
| Anesthetics, Local | 3 | 2015 | 79 | 0.560 |
Why?
|
| Neuralgia | 2 | 2015 | 48 | 0.560 |
Why?
|
| Male | 37 | 2020 | 19091 | 0.550 |
Why?
|
| Cyclohexanecarboxylic Acids | 3 | 2006 | 21 | 0.550 |
Why?
|
| Amines | 3 | 2006 | 22 | 0.550 |
Why?
|
| Denervation | 4 | 2008 | 13 | 0.530 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 404 | 0.520 |
Why?
|
| Stellate Ganglion | 1 | 2015 | 1 | 0.510 |
Why?
|
| Ventricular Fibrillation | 1 | 2015 | 5 | 0.510 |
Why?
|
| Medulla Oblongata | 5 | 2007 | 51 | 0.500 |
Why?
|
| Disability Evaluation | 3 | 2014 | 238 | 0.490 |
Why?
|
| Receptors, Opioid, mu | 4 | 2007 | 31 | 0.490 |
Why?
|
| Phantom Limb | 1 | 2014 | 4 | 0.480 |
Why?
|
| Receptors, Opioid, delta | 5 | 2007 | 12 | 0.460 |
Why?
|
| Middle Aged | 21 | 2019 | 11824 | 0.460 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2015 | 353 | 0.460 |
Why?
|
| Schools, Medical | 1 | 2014 | 43 | 0.460 |
Why?
|
| Exercise Therapy | 2 | 2014 | 268 | 0.440 |
Why?
|
| Anesthesiology | 1 | 2014 | 49 | 0.430 |
Why?
|
| Faculty, Medical | 1 | 2014 | 78 | 0.430 |
Why?
|
| Diabetic Neuropathies | 2 | 2013 | 24 | 0.430 |
Why?
|
| Spinal Cord | 4 | 2004 | 130 | 0.410 |
Why?
|
| Delivery of Health Care | 1 | 2014 | 159 | 0.410 |
Why?
|
| Nociceptors | 6 | 2004 | 39 | 0.400 |
Why?
|
| Health Behavior | 1 | 2013 | 231 | 0.400 |
Why?
|
| Female | 26 | 2020 | 19859 | 0.390 |
Why?
|
| Osteoarthritis | 1 | 2012 | 79 | 0.390 |
Why?
|
| Postoperative Care | 3 | 2019 | 76 | 0.390 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2022 | 57 | 0.350 |
Why?
|
| Adult | 14 | 2020 | 9327 | 0.350 |
Why?
|
| Anemia, Sickle Cell | 2 | 2020 | 43 | 0.340 |
Why?
|
| Walking | 4 | 2014 | 208 | 0.340 |
Why?
|
| Catheter Ablation | 2 | 2008 | 66 | 0.340 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2017 | 504 | 0.330 |
Why?
|
| Societies, Medical | 3 | 2018 | 161 | 0.330 |
Why?
|
| Pain Threshold | 2 | 2008 | 92 | 0.320 |
Why?
|
| Ketamine | 2 | 2018 | 18 | 0.320 |
Why?
|
| Aged | 14 | 2018 | 10288 | 0.310 |
Why?
|
| Hyperalgesia | 4 | 2007 | 78 | 0.310 |
Why?
|
| Patient Selection | 2 | 2022 | 276 | 0.300 |
Why?
|
| Spinal Diseases | 1 | 2007 | 16 | 0.300 |
Why?
|
| Inflammation | 4 | 2007 | 540 | 0.300 |
Why?
|
| Enkephalin, Ala(2)-MePhe(4)-Gly(5)- | 3 | 2007 | 14 | 0.300 |
Why?
|
| Cervical Vertebrae | 1 | 2007 | 44 | 0.290 |
Why?
|
| Risk Factors | 9 | 2019 | 3851 | 0.290 |
Why?
|
| Oligopeptides | 4 | 2007 | 45 | 0.280 |
Why?
|
| Orthopedic Procedures | 1 | 2007 | 89 | 0.280 |
Why?
|
| United States | 7 | 2020 | 3925 | 0.280 |
Why?
|
| Ganglia, Spinal | 2 | 2006 | 65 | 0.280 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 73 | 0.270 |
Why?
|
| Analgesia | 2 | 2016 | 29 | 0.260 |
Why?
|
| Decision Support Techniques | 2 | 2018 | 128 | 0.260 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 3988 | 0.260 |
Why?
|
| Rats, Sprague-Dawley | 9 | 2007 | 738 | 0.250 |
Why?
|
| Physical Endurance | 3 | 2013 | 35 | 0.250 |
Why?
|
| Nerve Block | 3 | 2012 | 50 | 0.240 |
Why?
|
| Enkephalins | 2 | 2001 | 10 | 0.240 |
Why?
|
| Gait | 3 | 2014 | 140 | 0.230 |
Why?
|
| Radiosurgery | 1 | 2007 | 356 | 0.230 |
Why?
|
| Postural Balance | 1 | 2016 | 182 | 0.230 |
Why?
|
| Brain | 3 | 2019 | 949 | 0.220 |
Why?
|
| Pesticides | 1 | 2016 | 200 | 0.220 |
Why?
|
| Efferent Pathways | 1 | 2003 | 8 | 0.220 |
Why?
|
| Rats | 9 | 2007 | 1586 | 0.220 |
Why?
|
| Occupational Exposure | 1 | 2016 | 233 | 0.220 |
Why?
|
| Receptors, Opioid | 1 | 2003 | 12 | 0.220 |
Why?
|
| Naproxen | 1 | 2002 | 7 | 0.220 |
Why?
|
| Injections, Spinal | 3 | 2016 | 108 | 0.220 |
Why?
|
| Acetates | 1 | 2002 | 10 | 0.220 |
Why?
|
| Algorithms | 2 | 2017 | 495 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 291 | 0.210 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 245 | 0.210 |
Why?
|
| Research Design | 2 | 2017 | 310 | 0.210 |
Why?
|
| Neurons | 2 | 2003 | 409 | 0.200 |
Why?
|
| Consensus | 5 | 2019 | 85 | 0.200 |
Why?
|
| Muscle Strength | 2 | 2013 | 159 | 0.200 |
Why?
|
| Knee Joint | 1 | 2023 | 142 | 0.200 |
Why?
|
| Anesthesia, Conduction | 2 | 2018 | 25 | 0.200 |
Why?
|
| Hematology | 1 | 2020 | 8 | 0.180 |
Why?
|
| Predictive Value of Tests | 3 | 2013 | 874 | 0.180 |
Why?
|
| Animals | 12 | 2010 | 7450 | 0.180 |
Why?
|
| Body Mass Index | 3 | 2013 | 916 | 0.170 |
Why?
|
| Lower Extremity | 1 | 2020 | 100 | 0.170 |
Why?
|
| Periaqueductal Gray | 1 | 2019 | 2 | 0.170 |
Why?
|
| User-Computer Interface | 1 | 2019 | 51 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 942 | 0.170 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2017 | 13 | 0.150 |
Why?
|
| Classification | 1 | 2017 | 1 | 0.150 |
Why?
|
| Analgesia, Epidural | 2 | 2010 | 51 | 0.150 |
Why?
|
| Microinjections | 4 | 2001 | 35 | 0.150 |
Why?
|
| Medical History Taking | 1 | 2017 | 37 | 0.150 |
Why?
|
| Medical Informatics | 1 | 2016 | 27 | 0.140 |
Why?
|
| Cluster Analysis | 1 | 2016 | 128 | 0.140 |
Why?
|
| Lumbar Vertebrae | 2 | 2007 | 97 | 0.140 |
Why?
|
| Ambulatory Care Facilities | 1 | 2016 | 83 | 0.140 |
Why?
|
| Cross-Over Studies | 2 | 2014 | 93 | 0.140 |
Why?
|
| Placebos | 1 | 2015 | 63 | 0.130 |
Why?
|
| Organizational Case Studies | 1 | 2015 | 11 | 0.130 |
Why?
|
| Quality Assurance, Health Care | 1 | 2016 | 72 | 0.130 |
Why?
|
| Evidence-Based Medicine | 4 | 2020 | 215 | 0.130 |
Why?
|
| Neurosurgical Procedures | 1 | 2016 | 99 | 0.130 |
Why?
|
| Electric Countershock | 1 | 2015 | 11 | 0.130 |
Why?
|
| Sympathectomy | 1 | 2015 | 21 | 0.130 |
Why?
|
| Volleyball | 1 | 2015 | 1 | 0.130 |
Why?
|
| Terminology as Topic | 3 | 2019 | 64 | 0.130 |
Why?
|
| Receptors, Opioid, kappa | 2 | 2008 | 24 | 0.130 |
Why?
|
| Family Practice | 1 | 2015 | 51 | 0.120 |
Why?
|
| Drug Synergism | 4 | 2007 | 66 | 0.120 |
Why?
|
| Soccer | 1 | 2015 | 19 | 0.120 |
Why?
|
| Young Adult | 3 | 2019 | 2603 | 0.120 |
Why?
|
| Qualitative Research | 3 | 2020 | 166 | 0.120 |
Why?
|
| Retrospective Studies | 5 | 2015 | 3488 | 0.120 |
Why?
|
| Drug Administration Schedule | 3 | 2019 | 272 | 0.120 |
Why?
|
| Spinal Nerves | 1 | 2015 | 65 | 0.120 |
Why?
|
| Overweight | 2 | 2013 | 276 | 0.120 |
Why?
|
| Brain Concussion | 1 | 2015 | 62 | 0.120 |
Why?
|
| Injections, Intra-Articular | 1 | 2014 | 16 | 0.120 |
Why?
|
| False Positive Reactions | 1 | 2014 | 31 | 0.120 |
Why?
|
| Efficiency | 1 | 2014 | 18 | 0.120 |
Why?
|
| Joints | 1 | 2013 | 13 | 0.120 |
Why?
|
| Baseball | 1 | 2015 | 41 | 0.120 |
Why?
|
| Neuralgia, Postherpetic | 1 | 2013 | 6 | 0.110 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2013 | 19 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2015 | 168 | 0.110 |
Why?
|
| Cost of Illness | 1 | 2013 | 70 | 0.110 |
Why?
|
| Patient Education as Topic | 1 | 2015 | 271 | 0.110 |
Why?
|
| Health Policy | 1 | 2014 | 82 | 0.110 |
Why?
|
| Affect | 1 | 2013 | 69 | 0.110 |
Why?
|
| Phobic Disorders | 1 | 2013 | 9 | 0.110 |
Why?
|
| Chronic Disease | 3 | 2013 | 400 | 0.110 |
Why?
|
| Time Factors | 5 | 2019 | 2146 | 0.110 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2013 | 51 | 0.110 |
Why?
|
| Health Care Surveys | 1 | 2014 | 186 | 0.110 |
Why?
|
| Patient Care Team | 1 | 2013 | 129 | 0.110 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 136 | 0.110 |
Why?
|
| Celiac Plexus | 1 | 2012 | 3 | 0.100 |
Why?
|
| Databases, Factual | 1 | 2014 | 349 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2019 | 1431 | 0.100 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 564 | 0.100 |
Why?
|
| Incidence | 3 | 2019 | 1192 | 0.100 |
Why?
|
| Mobility Limitation | 1 | 2013 | 219 | 0.100 |
Why?
|
| Adolescent | 4 | 2019 | 3511 | 0.090 |
Why?
|
| Behavior, Addictive | 1 | 2010 | 32 | 0.090 |
Why?
|
| Pancreatic Neoplasms | 1 | 2012 | 140 | 0.090 |
Why?
|
| Checklist | 1 | 2010 | 38 | 0.090 |
Why?
|
| Diet | 1 | 2012 | 385 | 0.090 |
Why?
|
| Delphi Technique | 2 | 2019 | 40 | 0.080 |
Why?
|
| Epidural Space | 1 | 2009 | 8 | 0.080 |
Why?
|
| Muscle, Skeletal | 1 | 2013 | 513 | 0.080 |
Why?
|
| Steroids | 1 | 2009 | 38 | 0.080 |
Why?
|
| Regression Analysis | 3 | 2013 | 293 | 0.080 |
Why?
|
| HIV Infections | 1 | 2013 | 394 | 0.080 |
Why?
|
| Infusions, Intravenous | 2 | 2018 | 99 | 0.080 |
Why?
|
| Neck Pain | 1 | 2007 | 6 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 1323 | 0.080 |
Why?
|
| Radiculopathy | 1 | 2007 | 5 | 0.070 |
Why?
|
| Models, Statistical | 1 | 2008 | 173 | 0.070 |
Why?
|
| Hindlimb | 3 | 2007 | 54 | 0.070 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2007 | 48 | 0.070 |
Why?
|
| Sex Characteristics | 1 | 2008 | 169 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 163 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2007 | 109 | 0.070 |
Why?
|
| Forecasting | 1 | 2007 | 144 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 121 | 0.070 |
Why?
|
| Nortriptyline | 1 | 2006 | 2 | 0.070 |
Why?
|
| Carbamazepine | 1 | 2006 | 5 | 0.070 |
Why?
|
| Thoracotomy | 1 | 2006 | 21 | 0.070 |
Why?
|
| Reaction Time | 2 | 2007 | 117 | 0.070 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2007 | 629 | 0.070 |
Why?
|
| Fluoroscopy | 1 | 2006 | 40 | 0.070 |
Why?
|
| Mastectomy | 1 | 2006 | 65 | 0.070 |
Why?
|
| Anticonvulsants | 1 | 2006 | 65 | 0.070 |
Why?
|
| Adrenergic alpha-Antagonists | 2 | 2003 | 24 | 0.070 |
Why?
|
| Prevalence | 1 | 2008 | 979 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2008 | 1012 | 0.060 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 82 | 0.060 |
Why?
|
| Calcium | 2 | 2002 | 304 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2016 | 895 | 0.060 |
Why?
|
| Receptors, GABA | 1 | 2003 | 6 | 0.050 |
Why?
|
| Serotonin Antagonists | 1 | 2003 | 5 | 0.050 |
Why?
|
| GABA Antagonists | 1 | 2003 | 12 | 0.050 |
Why?
|
| Medicare | 1 | 2004 | 206 | 0.050 |
Why?
|
| Receptors, Serotonin | 1 | 2003 | 7 | 0.050 |
Why?
|
| Narcotics | 1 | 2003 | 16 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2003 | 79 | 0.050 |
Why?
|
| Quality of Life | 1 | 2008 | 924 | 0.050 |
Why?
|
| Research Subjects | 1 | 2022 | 17 | 0.050 |
Why?
|
| Electronics | 1 | 2022 | 14 | 0.050 |
Why?
|
| Calcium Channels | 1 | 2002 | 57 | 0.050 |
Why?
|
| Exercise Test | 2 | 2013 | 225 | 0.050 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 2001 | 4 | 0.050 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 75 | 0.050 |
Why?
|
| Benzeneacetamides | 1 | 2001 | 3 | 0.050 |
Why?
|
| Chemokines | 1 | 2001 | 36 | 0.050 |
Why?
|
| Pyrrolidines | 1 | 2001 | 12 | 0.050 |
Why?
|
| North Carolina | 1 | 2016 | 1514 | 0.050 |
Why?
|
| Somatostatin | 1 | 2001 | 11 | 0.050 |
Why?
|
| Naltrexone | 1 | 2001 | 18 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2016 | 764 | 0.050 |
Why?
|
| Indiana | 1 | 2020 | 26 | 0.050 |
Why?
|
| Peptides | 1 | 2001 | 119 | 0.050 |
Why?
|
| Skin Temperature | 1 | 2000 | 16 | 0.040 |
Why?
|
| Age Factors | 2 | 2013 | 1187 | 0.040 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 1999 | 33 | 0.040 |
Why?
|
| Enkephalin, D-Penicillamine (2,5)- | 1 | 1999 | 5 | 0.040 |
Why?
|
| Norepinephrine | 1 | 1999 | 77 | 0.040 |
Why?
|
| Rest | 1 | 2019 | 54 | 0.040 |
Why?
|
| Child | 2 | 2020 | 2425 | 0.040 |
Why?
|
| Neural Pathways | 1 | 2019 | 94 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2013 | 1824 | 0.040 |
Why?
|
| Logistic Models | 2 | 2015 | 777 | 0.040 |
Why?
|
| Brain Mapping | 1 | 2019 | 178 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2012 | 537 | 0.040 |
Why?
|
| Peptide Fragments | 1 | 2001 | 398 | 0.040 |
Why?
|
| Nerve Net | 1 | 2019 | 123 | 0.040 |
Why?
|
| Syndrome | 1 | 2017 | 73 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2020 | 161 | 0.040 |
Why?
|
| Quality of Health Care | 1 | 2018 | 147 | 0.040 |
Why?
|
| Public-Private Sector Partnerships | 1 | 2017 | 4 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2016 | 2277 | 0.040 |
Why?
|
| Decision Making | 1 | 2018 | 194 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 2016 | 99 | 0.030 |
Why?
|
| Decision Trees | 1 | 2015 | 31 | 0.030 |
Why?
|
| Random Allocation | 1 | 2015 | 218 | 0.030 |
Why?
|
| ROC Curve | 1 | 2015 | 167 | 0.030 |
Why?
|
| Sports | 1 | 2015 | 35 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 297 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2018 | 1527 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2015 | 184 | 0.030 |
Why?
|
| Self Concept | 1 | 2013 | 42 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2008 | 2271 | 0.030 |
Why?
|
| Obesity, Morbid | 1 | 2013 | 71 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2013 | 257 | 0.020 |
Why?
|
| African Americans | 1 | 2019 | 1428 | 0.020 |
Why?
|
| Iatrogenic Disease | 1 | 2010 | 15 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 62 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 899 | 0.020 |
Why?
|
| Substance-Related Disorders | 1 | 2010 | 127 | 0.020 |
Why?
|
| Injections, Epidural | 1 | 2009 | 9 | 0.020 |
Why?
|
| Lumbosacral Region | 1 | 2009 | 11 | 0.020 |
Why?
|
| Freund's Adjuvant | 1 | 2007 | 2 | 0.020 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 2007 | 20 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2007 | 96 | 0.020 |
Why?
|
| Weight-Bearing | 1 | 2007 | 40 | 0.020 |
Why?
|
| Medical Records | 1 | 2007 | 76 | 0.020 |
Why?
|
| Radiography | 1 | 2007 | 376 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2007 | 523 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2004 | 22 | 0.020 |
Why?
|
| Sampling Studies | 1 | 2004 | 43 | 0.020 |
Why?
|
| Pneumonia | 1 | 2004 | 66 | 0.010 |
Why?
|
| Peripheral Nerves | 1 | 2004 | 62 | 0.010 |
Why?
|
| Odds Ratio | 1 | 2004 | 470 | 0.010 |
Why?
|
| Synaptic Transmission | 1 | 2004 | 116 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 686 | 0.010 |
Why?
|
| Prognosis | 1 | 2007 | 1498 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2001 | 2 | 0.010 |
Why?
|
| Receptors, CXCR4 | 1 | 2001 | 11 | 0.010 |
Why?
|
| Receptors, CCR4 | 1 | 2001 | 3 | 0.010 |
Why?
|
| Bradykinin | 1 | 2001 | 12 | 0.010 |
Why?
|
| Receptors, Chemokine | 1 | 2001 | 9 | 0.010 |
Why?
|
| Substance P | 1 | 2001 | 20 | 0.010 |
Why?
|
| Capsaicin | 1 | 2001 | 24 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2001 | 53 | 0.010 |
Why?
|
| Tail | 1 | 2001 | 5 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2001 | 48 | 0.010 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2001 | 32 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2001 | 70 | 0.010 |
Why?
|
| Neurons, Afferent | 1 | 2001 | 55 | 0.010 |
Why?
|
| Yohimbine | 1 | 1999 | 4 | 0.010 |
Why?
|
| Dexmedetomidine | 1 | 1999 | 8 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2001 | 508 | 0.010 |
Why?
|
| Anesthesia, Spinal | 1 | 1999 | 20 | 0.010 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 1999 | 42 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2001 | 833 | 0.010 |
Why?
|